As germs outpace antibiotics, developers hunt for new solutions

The rise of antibiotic-resistant bacteria has become a global scourge, and researchers across academia and industry are taking novel steps to fight back. As The Wall Street Journal reports, Boston University scientists have discovered that adding trace amounts of silver to a standard vancomycin treatment can help the antibiotic better combat E. coli, and investigators at Merck ($MRK) are developing MK-7655, which targets the bacteria-housed enzyme beta-lactamase in an effort to break down defenses and boost antibiotic efficacy. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.